Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Derisomaltose in Heart Failure With Preserved Ejection Fraction and Iron Deficiency
NCT04945707Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2021
- Primary completion
- Jun 2026
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric derisomaltose in heart failure with preserved ejection fraction (HFpEF), iron deficiency anemia (IDA), sponsored by Massachusetts General Hospital. Started Nov 2021; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04945707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945707.